# Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study

> **NCT04069221** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 26 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Single oral dose of 800 mg OZ439
- **DRUG:** Single oral dose of 400 mg OZ439
- **DRUG:** Single oral dose of cobicistat
- **DRUG:** iv infusion of [14C]-OZ439

## Key facts

- **NCT ID:** NCT04069221
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-28
- **Primary completion:** 2017-05-30
- **Final completion:** 2017-05-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04069221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04069221, "Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04069221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*